T cell-based immunotherapies, including immune checkpoint blockade and chimeric antigen receptor (CAR) T cells, have transformed outcomes in several cancers. Yet their effectiveness is routinely undermined by two barriers built by the tumor itself. The first is intrinsic resistance: tumor cells downregulate antigen presentation and display checkpoint molecules such as PD-L1 and CD73 that shut down approaching T cells. The second is the tumor microenvironment itself, which becomes dominated by M2-like tumor-associated macrophages, cells that secrete immunosuppressive cytokines, impair antigen presentation, and actively suppress anti-tumor responses. Most therapeutic strategies address one barrier at a time; the new work demonstrates that a single microRNA can act on both.

The researchers focused on microRNAs, short non-coding RNA molecules of roughly 22 nucleotides that bind complementary sequences in messenger RNAs and dampen protein production. Because each microRNA can regulate dozens of targets at once, they are uniquely positioned to orchestrate broad, coordinated changes in cell behavior, a property the team set out to exploit deliberately. Their central question was whether miR-155-5p, and a related candidate called miR-3535, could drive functional reprogramming of both tumor cells and macrophages in a concerted fashion.

Experimentally, the approach was straightforward but comprehensive. Human tumor cell lines drawn from several different cancer entities were transfected with synthetic miR-155-5p or miR-3535, and the resulting changes in immune checkpoint molecule expression and cell proliferation were measured at both the transcript and protein level. In parallel, M2-polarized macrophages generated from peripheral blood mononuclear cells of healthy donors received the same microRNA treatment. The team then profiled cytokine secretion by enzyme-linked immunosorbent assay and carried out transcriptomic analysis, combining RNA sequencing with microarray-based gene expression profiling, to map the macrophage polarization states and immune-regulatory pathways altered by treatment. Transcription factor activity and gene set enrichment analyses were used to identify the regulatory circuits at work.

The results in tumor cells were striking. Both microRNAs reduced expression of CD73, encoded by the NT5E gene, an ectoenzyme that degrades extracellular ATP into immunosuppressive adenosine and is widely regarded as a driver of tumor immune escape. miR-155-5p went further, also suppressing PD-L1 (CD274), the ligand targeted by some of the most widely used checkpoint inhibitor drugs. Knocking down both molecules in a single step effectively removes two of the brakes tumors place on T cells, one that blocks T cell activation through the PD-1 axis and one that poisons the metabolic environment around the tumor.

The macrophage findings were equally significant. When M2-like macrophages, the immunosuppressive, wound-healing subtype that accumulates in tumors, were transfected with either microRNA, they shifted toward a pro-inflammatory M1-like phenotype. This conversion was measurable functionally: treated macrophages secreted markedly more TNFα, a cytokine with direct anti-tumor activity, and CXCL10, a chemokine that recruits activated T cells into tissues. Gene expression analysis confirmed the induction of M1-associated genes across the board.

The transcriptomic data revealed the mechanism in finer detail. MicroRNA treatment activated inflammatory signaling pathways driven by STAT1, a signal transducer and activator of transcription, and by interferon regulatory factors, the downstream effectors of interferon signaling that define the classical inflammatory macrophage state. At the same time, the activity of ZNF703, a zinc finger transcription factor that the study identifies as a transcriptional hub associated with M2 macrophage infiltration and poor clinical prognosis, was reduced. In other words, the microRNAs did not merely nudge macrophages; they flipped the regulatory logic of the cell, amplifying the inflammatory program while simultaneously quieting a master regulator of the tumor-permissive state.

A further observation points to a possible bonus effect on the anti-tumor immune response itself. Both microRNAs increased expression of TAP1, the transporter associated with antigen processing 1, a critical component of the machinery that loads peptide fragments onto MHC class I molecules for display to cytotoxic T cells. Enhanced TAP1 expression suggests improved antigen-processing capacity, potentially making tumor cells and antigen-presenting cells more visible to the immune system. This is particularly relevant because loss of antigen presentation is a well-documented route by which tumors escape both natural immune surveillance and T cell-based therapies.

Beyond their immunological effects, both microRNAs exerted direct anti-proliferative effects across tumor cell lines from multiple entities. That the same molecule slows tumor growth while simultaneously reversing checkpoint expression and repolarizing macrophages is what distinguishes this work from more narrowly targeted approaches. The findings link tumor cell plasticity to neutralization of the immunosuppressive tumor environment within a single regulatory mechanism, rather than treating these as separate problems requiring separate drugs.

The broader implications for cancer immunotherapy are considerable. Current strategies to overcome immune resistance typically involve combining checkpoint inhibitors with each other or with chemotherapy, radiation, or macrophage-targeting agents, an approach that multiplies toxicity and cost. A microRNA-based strategy that acts on several fronts at once could, in principle, simplify this combinatorial challenge. The authors note that the findings support further investigation of microRNA-based strategies in cancer immunotherapy, and the field has already developed delivery tools, including lipid nanoparticles, that could in theory carry synthetic microRNAs to tumors and tumor-associated immune cells in vivo.

Caution is warranted, as always in preclinical work. The experiments were conducted in cell lines and in donor-derived macrophages, not in patients, and the challenge of delivering a microRNA selectively to the right cells in a living tumor remains formidable. miR-155 in particular is a pleiotropic molecule with roles in inflammation and immunity that cut both ways; systemic elevation could carry inflammatory risks, and past clinical experience with nucleic acid therapeutics has taught the field to be skeptical of simple delivery assumptions. The question of dose, timing, and tissue specificity will need to be answered in animal models and, eventually, carefully designed clinical studies.

Even so, the conceptual contribution is substantial. The study demonstrates that microRNAs are capable of coordinating anti-tumor effects across different cell types, a property that individual protein-targeting drugs rarely possess. If the coordinated reprogramming seen in vitro can be reproduced in vivo, miR-155-5p and miR-3535 would represent a template for a new class of immunotherapy, one that does not simply block a single checkpoint or deplete a single cell population, but rewires the conversation between tumor and immune system at multiple points simultaneously. At a time when the majority of patients still do not benefit from existing immunotherapies, strategies that address tumor-intrinsic resistance and microenvironmental suppression in one stroke are exactly the kind of innovation the field has been searching for.

The study, led by Assistant Professor Ricardo Iván Martínez-Zamudio from Rutgers Robert Wood Johnson Medical School, highlights that a substantial proportion of patient-derived CD8+ T cells are often in a dysfunctional state known as senescence. Senescent T cells exhibit diminished proliferative capacity, impaired migratory abilities, and significantly reduced cytotoxic function—all of which hamper the efficacy of CAR T-cell treatments. These senescent cells, which accumulate naturally with age, cease dividing but persist in the immune system, secreting low levels of inflammatory molecules that contribute to chronic inflammation and immune system dysregulation.

Notably, senescence is not simply an artifact of chronological aging. The study reveals that the molecular signatures of senescent CD8+ T cells are remarkably consistent across age groups, indicating that the senescence program is pre-established early in adulthood. The difference between younger and older individuals lies primarily in the proportion of T cells that activate this program, with older populations exhibiting substantially higher burdens of senescent cells—up to 80% in some cases. This discovery challenges traditional conceptions of immune aging as purely a function of time and instead points to an intrinsic, age-independent mechanism driving the transition to senescence.

To elucidate the molecular underpinnings of T-cell senescence, the Rutgers team performed advanced gene expression and chromatin landscape analyses on sorted populations of senescent and non-senescent CD8+ T cells from both young and old donors. Chromatin, which packages DNA inside the nucleus, controls gene accessibility and thus influences cellular identity and function. The researchers identified a core transcriptional network—comprising several key transcription factors—that orchestrates the senescence state. These transcription factors, acting as molecular switches to turn specific genes on or off, were found to be similarly expressed regardless of donor age, underscoring the age-independent nature of the senescence program.

Intriguingly, interventions targeting these transcription factors demonstrated potential therapeutic effects. By employing chemical inhibitors and genetic tools to reduce levels of these critical proteins, the team was able to dampen the inflammatory gene expression profile typical of senescent cells. One transcription factor, in particular, when suppressed, partially restored gene expression patterns associated with active, non-senescent T cells, suggesting pathways that might reverse or modulate senescent phenotypes. Although the recovery of proliferative function was modest, these findings open exciting avenues for enhancing the quality of T cells used in CAR T-cell manufacturing, potentially improving treatment outcomes.

This work has immediate implications for the field of cancer immunotherapy. The Rutgers researchers retrospectively analyzed clinical trial data from lymphoma patients who received CAR T-cell therapy and found that those whose starting T cells exhibited strong senescence signatures were significantly less likely to respond to treatment successfully. Conversely, patients with more ‘youthful’ T-cell profiles, displaying fewer senescent markers, showed better therapeutic outcomes. These correlations suggest that senescence profiling before manufacturing could serve as a predictive biomarker, allowing clinicians to identify patients unlikely to benefit from standard CAR T-cell products and guiding alternative therapeutic strategies.

Looking forward, the team plans to validate these findings in prospective clinical studies and, in collaboration with the Rutgers Cancer Institute, is exploring the feasibility of incorporating senescence assessments into CAR T-cell production protocols. Such innovations could lead to more personalized immunotherapies, tailored not just to tumor characteristics but also to the intrinsic quality of a patient’s immune cells.

Beyond oncology, the study sheds light on fundamental aspects of aging biology and the immune system’s decline over time. Senescent immune cells accumulate with age and contribute to a state known as “inflammaging,” characterized by chronic, low-grade inflammation implicated in cardiovascular disease, autoimmune disorders, and other age-associated pathologies. The researchers found that their senescence signatures were enriched not only in cancer patients but also in individuals suffering from active lupus, suggesting that the molecular pathways governing T-cell senescence may be broadly relevant to numerous inflammatory and immune-mediated diseases.

At its core, this research challenges existing paradigms of immunosenescence by demonstrating that the transition of CD8+ T cells into a senescent state is a programmed, potentially reversible process, rather than an inevitable consequence of aging. By identifying and targeting the transcription factors that regulate this program, it may become possible to rejuvenate senescent T cells or replace them with more effective immune effectors, thereby enhancing the efficacy of immunotherapies and improving health outcomes in older populations.

This work enhances the collective understanding of how immune cell aging impacts therapeutic strategies and underscores the necessity of integrating cellular quality control into personalized medicine. The implications extend far beyond CAR T-cell therapy and oncology, positioning immune senescence as a central player in age-related disease progression and immune dysfunction.

As researchers continue to unravel the complexities of the senescence program and develop novel approaches to modulate it, the possibility emerges of harnessing the immune system’s full potential, even in aged individuals, to combat cancer and other chronic diseases. This pioneering study thus represents a significant step toward more effective, precision-based immunotherapies that account for the intricate biology of the human immune system.

Subject of Research: CD8+ T cell senescence and its impact on CAR T-cell therapy efficacy
Article Title: Age-independent and targetable transcription factor networks regulating CD8+ T cell senescence in aging humans
News Publication Date: 13-Feb-2026
Web References: http://dx.doi.org/10.1016/j.celrep.2025.116795
Keywords: CAR T-cell therapy, CD8+ T cells, immune senescence, transcription factors, immunotherapy, aging, chronic inflammation, cancer immunology, lymphomas, gene expression, chromatin landscape, immune aging

Conventional CAR T cell therapies have revolutionized the treatment of B-cell malignancies by genetically engineering a patient’s own T cells to recognize and destroy cancer cells expressing the CD19 antigen. However, despite remarkable initial successes, several critical challenges emerge. One of the foremost issues is antigen escape, wherein tumor cells downregulate or lose the targeted antigen, thereby evading immune recognition. This results in relapse and limits long-term efficacy. Another formidable challenge is the use of allogeneic, or donor-derived, CAR T cells that, while offering advantages such as immediate availability and uniform quality, provoke alloimmune responses that can lead to graft-versus-host disease and rapid CAR T cell clearance.

The innovation reported by Zhang, Li, O’Dair, and colleagues combines these two elements in an elegant and highly functional design. By arming CD19-targeting CAR T cells with an additional chimeric antigen receptor directed against CD70, a molecule implicated in alloimmune rejection, the researchers have orchestrated a dual-function therapeutic agent capable of both sustainable tumor targeting and evasion of host immune rejection. CD70 expression is upregulated on activated immune cells during alloimmune reactions, making it an ideal target to suppress these unwanted immune responses without broadly compromising immune function.

Technically, the study employed sophisticated gene engineering techniques to generate bispecific CAR T cells, which simultaneously express CARs against CD19 and CD70. The anti-CD70 CAR functions as a built-in immune checkpoint inhibitor, tempering the immune activation that prompts rejection of allogeneic T cells. This dual targeting paradigm enables the CAR T cells to persist longer in the host bloodstream, exert sustained cytotoxicity against malignant B cells, and crucially, reduce the incidence of graft-versus-host complications. The researchers validated these effects in rigorous in vitro assays and robust in vivo models that recapitulate the tumor microenvironment and alloimmune interactions.

A pivotal mechanistic insight from the study reveals that the presence of the anti-CD70 CAR diminishes host T cell and natural killer (NK) cell-mediated destruction of the infused allogeneic CAR T cells. By selectively erasing the lymphocyte populations responsible for rejection, the engineered therapies effectively cloak themselves, maintaining their cytolytic activity against tumor cells. This finding not only exemplifies the power of precise immunomodulation but also extends the therapeutic window, allowing repeated dosing regimens that were previously untenable with allogeneic strategies.

The implications of overcoming antigen escape are equally transformative. Tumor heterogeneity and plasticity have long imperiled the durability of CAR T cell therapies, as cancer cells continuously evolve to circumvent immune targeting. The augmented allogeneic CAR T cells demonstrate an enhanced ability to recognize variant or residual populations of B cells by relying on dual antigen recognition. Should CD19 expression diminish, the therapy’s anti-CD70 arm helps maintain selective pressure against the tumor environment’s supportive immune components, disrupting the mechanisms that favor tumor persistence and relapse.

Clinically, this dual targeting approach has the potential to expand off-the-shelf CAR T cell therapies dramatically. Current autologous CAR T protocols involve complex, time-intensive manufacturing and relinquish treatment opportunities to patients with aggressive disease progression. Ready-to-use allogeneic CAR T cell products, equipped with anti-CD70 CARs to circumvent rejection, could democratize access to lifesaving immunotherapies globally. Moreover, the decreased risk of graft-versus-host disease will alleviate the burden of severe toxicities, improving patient safety profiles and quality of life during treatment.

Beyond hematological malignancies, the principles elucidated in this study open avenues for targeting solid tumors, where antigen heterogeneity and immune modulation represent formidable barriers. The ability to engineer multi-specific CAR T cells that simultaneously eliminate tumor cells and modulate the host immune response may be applicable to an array of cancers and chronic infections. This paradigm underscores a shift toward intelligent, adaptable cell therapies that orchestrate complex immune dynamics rather than relying on singular antigen targeting.

The research team also highlighted the scalability and manufacturability of their bispecific CAR T cells, utilizing lentiviral vectors and optimized culture conditions to preserve cell viability and functional potency. This addresses critical translational hurdles, ensuring that promising preclinical findings can be efficiently leveraged for rapid clinical development. As a result, several clinical trials investigating similar constructs are anticipated within the next few years, potentially accelerating the approval timeline for next-generation CAR T products.

Safety remains paramount in CAR T cell therapies, particularly with the introduction of new antigen targets and combined modalities. The anti-CD70 CAR design incorporates safety switches to facilitate the selective depletion of infused T cells in the event of unanticipated toxicities, reflecting a robust risk mitigation strategy. Continued monitoring of cytokine release syndrome and neurotoxicity in preclinical models has shown favorable profiles, but the authors caution that comprehensive clinical evaluation will be necessary to confirm these results.

This work also underscores the importance of integrating immunological insights with bioengineering advances. The strategic targeting of CD70—an immune checkpoint molecule beyond classical PD1/CTLA4 axes—demonstrates how deeper understanding of immune cell interactions can inform novel therapeutic strategies. Such innovations will likely become increasingly common as the field embraces complexity rather than shying away from it.

In conclusion, the study by Zhang and colleagues represents a monumental step forward in the evolution of CAR T cell therapy. By ingeniously combining allogeneic CD19 CAR T cells with an anti-rejection CD70 CAR, the team has addressed the twin issues of antigen escape and alloimmune rejection that have long constrained therapeutic efficacy. This breakthrough paves the way for safer, more effective, and more accessible immunotherapies that could transform cancer treatment paradigms worldwide.

As the scientific community eagerly awaits clinical trial data, this pioneering approach exemplifies the power of precision immunotherapy design to overcome biological challenges. It stands as a beacon for future research striving to harness the full potential of engineered immune cells against cancer and other diseases, setting a new standard for innovation and hope in medicine.

Subject of Research: Development of allogeneic CD19 CAR T cells enhanced with an anti-rejection CD70 CAR to prevent antigen escape and evade host alloimmune responses in cancer immunotherapy.

Article Title: Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses.

Article References:
Zhang, K., Li, Z., O’Dair, M.K. et al. Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71904-z

Image Credits: AI Generated

Fas Ligand (FasL), a protein expressed on the surface of activated immune cells, is a critical mediator of apoptosis, or programmed cell death. This process, indispensable for immune cells, allows them to identify and induce death in cells that are damaged or malignant. Among these immune warriors are CAR-T cells, a form of adoptive cell therapy engineered from the patient’s own immune system, which utilize FasL to trigger apoptosis in cancer cells. Yet, despite remarkable success against hematologic malignancies, CAR-T cell therapies have struggled to replicate such efficacy in solid tumors. The mystery behind this discrepancy now finds a compelling explanation rooted in evolutionary biology.

The team at UC Davis discovered that a single amino acid substitution in the human FasL protein — where serine replaces proline at position 153 — renders FasL highly susceptible to cleavage by plasmin. Plasmin is a proteolytic enzyme abundantly present within the microenvironments of aggressive solid tumors, including triple-negative breast cancer, colon cancer, and ovarian cancer. Through enzymatic cleavage, plasmin effectively disables FasL, neutralizing a key mechanism by which immune cells eliminate cancer cells. This evolutionary mutation appears unique to humans, as FasL in non-human primates such as chimpanzees retains proline at this position, making them less vulnerable to plasmin’s disruptive effects.

From an evolutionary perspective, this mutation in FasL might have been a trade-off that facilitated the development of larger, more complex human brains by modulating immune pathways, particularly pathways involved in cell death. However, in the context of oncology, this beneficial mutation for brain development becomes detrimental. By weakening FasL’s integrity, tumors exploit this vulnerability to disarm one of the immune system’s vital weapons, thus promoting immune evasion and enabling tumor progression and metastasis.

The study’s experimental investigations demonstrated that human immune cells, despite being activated and primed to attack cancer cells, often find their FasL function compromised within plasmin-rich tumor microenvironments. This discovery elegantly explains the limited success of immunotherapies like CAR-T and T-cell-based therapies in solid tumors, which are frequently characterized by an elevated presence of plasmin. In contrast, blood cancers, typically devoid of such high plasmin levels, are more susceptible to FasL-mediated immune eradication, accounting for the pronounced effectiveness of these therapies in hematologic malignancies.

Perhaps the most promising aspect of the UC Davis research lies in its therapeutic implications. By introducing plasmin inhibitors or developing antibodies engineered to shield FasL from plasmin-mediated cleavage, it is now conceivable to protect and restore FasL’s apoptotic function within the hostile solid tumor microenvironment. Such interventions could dramatically enhance the cytotoxic capabilities of immune cells, thereby potentiating immunotherapy responses in cancers that have previously been refractory to treatment.

Importantly, the research underscores a nuanced evolutionary dimension to cancer immunology, suggesting that intricate genetic variations shaped by millions of years of human development bear profound consequences for disease vulnerabilities. The authors emphasize the remarkable difference in cancer incidence and immune system efficacy between humans and their closest evolutionary relatives, primates, and invite deeper comparative study that may unlock further therapeutic avenues.

This breakthrough also challenges the oncology field to reconsider how immune escape mechanisms are understood and addressed. Rather than focusing solely on tumor cell mutations or immune checkpoint pathways, attention must now turn toward these evolutionary genetic alterations within key immune proteins and their interactions with the tumor milieu. Integrating such insights into the design of next-generation immunotherapies could bring personalized and more effective cancer treatments closer to reality.

As the researchers pursue further preclinical and clinical validation of their findings, the overall aim remains clear: to overcome the immunosuppressive tactics of plasmin-positive solid tumors by fortifying the immune system’s molecular arsenal. Should plasmin inhibition or FasL protection prove successful in human trials, it may usher in an unprecedented era of immunotherapy—one that can unlock durable and powerful anti-cancer responses in diverse solid tumors.

The implications of this discovery extend beyond oncology into the broader realm of immunobiology and evolutionary medicine. It highlights how evolutionary gains, such as those enabling cerebral complexity, can inadvertently introduce vulnerabilities in immune defense. Understanding these evolutionary trade-offs not only expands scientific knowledge but also guides the rational development of innovative therapies that reconcile our biological heritage with contemporary medical needs.

In conclusion, the identification of plasmin-mediated FasL inactivation as a unique human evolutionary vulnerability opens an exciting frontier in cancer research. It champions a paradigm wherein evolutionary biology informs precision medicine and offers hope for patients grappling with hard-to-treat solid tumors. As the research community embraces this knowledge, the prospect of more potent, personalized immunotherapies grows ever brighter, signaling a promising shift in the war against cancer.

Subject of Research: People

Article Title: Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy

News Publication Date: 1-Jul-2025

Web References:

• UC Davis Comprehensive Cancer Center
• Original Study in Nature Communications

References:

• Tushir-Singh, J. et al. Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. Nature Communications (2025). https://doi.org/10.1038/s41467-025-60990-0

Keywords:
Cancer research, Cancer, Cancer cells, Cancer immunotherapy, Primates, Nonhuman primates